Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG.APV-527
- Development stage
- Phase 2
- Lead developer
- Alligator Bioscience
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ALG.APV-527 is a bispecific agonistic antibody designed to target the co-stimulatory receptor 4-1BB (CD137) and the tumor-associated antigen 5T4. It selectively activates T cells and natural killer (NK) cells only upon simultaneous binding to both targets, which are preferentially expressed in tumor tissues such as triple negative breast cancer and renal cell carcinoma. This conditional activation aims to stimulate tumor-specific immune responses while minimizing systemic immune activation and associated toxicities like liver toxicity seen with other 4-1BB targeting agents. The molecule was developed using Alligator Bioscience’s proprietary ALLIGATOR-GOLD® antibody library combined with Aptevo Therapeutics’ ADAPTIR™ technology platform. It is currently under clinical investigation primarily for advanced solid tumors.
- Other names
- 4-1BB x 5T4 ADAPTIR Bispecific Antibodyanti-4-1BB/5T4 bispecific antibody ALG.APV-527
02
Targets
TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on ALG.APV-527.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG.APV-527.